Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis: Results from the Double-blind, Randomized, Phase 3 ReSTORE Trial Including the China Extension Study
Open Forum Infectious Diseases · 29.08.2025 · 12 (9)
DOI: 10.1093/ofid/ofaf555 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 15.09.2025. Verfasst von George R Thompson und 12 weiteren Autor:innen. Beteiligte Einrichtung: University of California Davis Medical Center, Sacramento, California, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cidara Therapeutics, Mundipharma.
Abstract (Originalsprache)
Background
Rezafungin is approved for use in adults with candidemia and/or invasive candidiasis (IC) based on data from the ReSTORE trial (NCT03667690), which demonstrated noninferior efficacy to caspofungin. For regulatory purposes, an additional cohort of patients from China was recruited to ReSTORE. Here, we compared rezafungin and caspofungin in patients with candidemia and/or IC through analysis of the ReSTORE global data plus the China extension study.
Methods
Adults with candidemia/IC were randomized (1:1) to receive weekly rezafungin (400/200 mg) or daily caspofungin (70/50 mg) for ≤28 days. Noninferiority was concluded for primary efficacy endpoints if the upper bound of the 95% confidence interval (CI) was below 20% for Day 30 all-cause mortality and if the weighted lower bound was above −20% for Day 14 global cure. Additional efficacy outcomes and safety were evaluated.
Results
Overall, 246 patients were randomized (122 rezafungin and 124 caspofungin). Noninferiority was demonstrated for both primary endpoints. Day 30 all-cause mortality was 25.2% and 24.8% (treatment difference 0.4%; 95% CI −10.8, 11.6) and Day 14 global cure was 56.5% and 57.3% (weighted treatment difference −1.0%; 95% CI −13.5, 11.6) with rezafungin versus caspofungin, respectively. Day 5 mycological eradication was numerically higher (68.7% vs 63.2%) and time to negative blood culture was numerically shorter (median 26.5 vs 38.8 h). Safety was comparable between groups; 53.3% (64/120; rezafungin) and 53.7% (66/123; caspofungin) of patients experienced serious adverse events.
Conclusions
This analysis confirmed the overall efficacy and safety of rezafungin demonstrated in ReSTORE, with early efficacy related to front-loaded exposure.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of California Davis Medical Center, Sacramento, California, USA.
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
- Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, Hangzhou, China.
- Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, CIBERINF, Barcelona, Spain.
- University of Cologne, and University Hospital Cologne, and German Centre for Infection Research (DZIF), Cologne, Germany.
ORCID-Profile: George R Thompson, Yunsong Yu, Alex Soriano, Oliver A Cornely, Bart Jan Kullberg, Matteo Bassetti
Förderung
- Cidara Therapeutics
- Mundipharma
Zitieren
APA
Thompson, G. R., Huang, H., Feng, S., Yu, Y., Soriano, A., Cornely, O. A., Kullberg, B. J., Pappas, P. G., Kollef, M., Vazquez, J. A., Honore, P. M., Cox, L., & Bassetti, M. (2025). Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis: Results from the Double-blind, Randomized, Phase 3 ReSTORE Trial Including the China Extension Study. Open Forum Infectious Diseases, 12(9). https://doi.org/10.1093/ofid/ofaf555
Vancouver
Thompson GR, Huang H, Feng S, Yu Y, Soriano A, Cornely OA, et al. Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis: Results from the Double-blind, Randomized, Phase 3 ReSTORE Trial Including the China Extension Study. Open Forum Infectious Diseases. 2025;12(9). doi:10.1093/ofid/ofaf555
BibTeX
@article{Thompson2025,
author = {Thompson, George R and Huang, Haihui and Feng, Sizhou and Yu, Yunsong and Soriano, Alex and Cornely, Oliver A and Kullberg, Bart Jan and Pappas, Peter G and Kollef, Marin and Vazquez, Jose A and Honore, Patrick M and Cox, Laura and Bassetti, Matteo},
title = {Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis: Results from the Double-blind, Randomized, Phase 3 ReSTORE Trial Including the China Extension Study},
journal = {Open Forum Infectious Diseases},
year = {2025},
volume = {12},
number = {9},
doi = {10.1093/ofid/ofaf555}
}
EUVIMED